Cardiol Therapeutics Inc
TSX:CRDL
Cardiol Therapeutics Inc
Net Change in Cash
Cardiol Therapeutics Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardiol Therapeutics Inc
TSX:CRDL
|
Net Change in Cash
-CA$5.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Net Change in Cash
$1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Net Change in Cash
-CA$56.5m
|
CAGR 3-Years
47%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Net Change in Cash
CA$31.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Net Change in Cash
-$53.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Net Change in Cash
CA$17m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-16%
|
|
Cardiol Therapeutics Inc
Glance View
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.
See Also
What is Cardiol Therapeutics Inc's Net Change in Cash?
Net Change in Cash
-5.3m
CAD
Based on the financial report for Mar 31, 2025, Cardiol Therapeutics Inc's Net Change in Cash amounts to -5.3m CAD.
What is Cardiol Therapeutics Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
12%
Over the last year, the Net Change in Cash growth was 75%.
You don't have any saved screeners yet